Polymyositis epidemiology report 2030 gives a thorough understanding of the Polymyositis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. 

Polymyositis Epidemiology Insight

DelveInsight&rsquo;s &lsquo;Polymyositis&mdash;Epidemiology Forecast&mdash;2030&rsquo; report delivers an in-depth understanding of the historical and forecasted epidemiology of Polymyositis in the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

<h2>Geographies Covered</h2>

<ul>
	<li>The United States</li>
	<li>EU5 (Germany, France, Italy, Spain, and the United Kingdom)</li>
	<li>Japan</li>
</ul>

Study Period: 2018&ndash;2030

<h2>Polymyositis: Disease Understanding</h2>

Polymyositis Overview

Polymyositis (PM) is a chronic autoimmune disease, and is a subtype of rare muscle diseases called idiopathic inflammatory myopathies (IIM).&nbsp; Other IIM subtypes include dermatomyositis (DM), inclusion body myositis (IBM), and necrotizing myopathy.

&nbsp;

Although PM is a rare disease, it is associated with increased morbidity and mortality due to its associated comorbid conditions, e.g., major vessels or gastrointestinal tract involvement, etc. It rarely presents in childhood and usually affects people above the age of 20 years. It is characterized by symmetrical proximal muscle weakness due to the involvement of endomysial layers of skeletal muscles versus DM, which involves the perimysial layers of muscles along with dermatological presentations.

&nbsp;

PM develops due to abnormal activation of cytotoxic T lymphocytes (CD8 cells) and macrophages against muscular antigens as well as the strong extrafusal muscular expression of major histocompatibility complex 1, causing damage to the endomysium of skeletal muscles.

&nbsp;

In PM, multiple small foci of inflammatory and necrotic changes and regenerative nodules can be seen on biopsy. Histopathological findings of PM show endomysial mononuclear infiltrate consisting of mostly CD8 T cells and macrophages along with necrotic myofibrils in the early stage. Late-stage changes include occluded capillaries secondary to inflammatory changes caused by endothelial damage and increased deposition of connective tissue and extracellular matrix. PM can be differentiated from IBM due to the presence of intracytoplasmic inclusion bodies in IBM and from DM due to perimysial infiltrates of CD4 cells as well as B lymphocytes. Polymyositis is a relatively challenging diagnosis due to the absence of dermatological findings compared to DM.

&nbsp;

PM is treated with a combination of different pharmacological and non-pharmacological modalities. Pharmacological treatment mainly includes corticosteroids. Prednisone and methylprednisolone are the most common corticosteroids used for polymyositis, with a starting dose of 1 mg/kg of prednisone a day. The steroids are tapered off gradually and not withdrawn suddenly. The second-line treatment option includes using immune-modulators (methotrexate, azathioprine, and cyclosporine) in those patients who either do not respond to steroids or develop severe adverse effects due to steroids usage. Cyclophosphamide, an immune-modulator, works efficiently, especially in patients with the involvement of the pulmonary interstitium. In the case of chronic refractory polymyositis, intravenous immunoglobulins (IVIG) can be used. Other therapies options include tacrolimus, a calcineurin inhibitor, which has proven beneficial in patients with a refractory disease with simultaneous use of prednisolone. Mycophenolate mofetil and the anti-CD20 monoclonal antibody rituximab have also been found to be useful in treating refractory cases of polymyositis.

&nbsp;

Without proper management, the morbidity and mortality from polymyositis are high. Thus, successful diagnosis and treatment at the initial stage are important.

<h2>Polymyositis: Epidemiology</h2>

The Polymyositis epidemiology division provides insights about the historical and current patient pool, along with the forecasted trend for every seven major countries. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the report also provides the diagnosed patient pool and their trends, along with assumptions undertaken.

&nbsp;

Key Findings

The disease epidemiology covered in the report provides historical and forecasted POLYMYOSITIS epidemiology segmented as the prevalent cases of Polymyositis, Gender-specific cases of Polymyositis, and Age-specific cases of Polymyositis. The report includes the prevalent scenario of Polymyositis in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2018 to 2030.

<h2>Country-wise Polymyositis Epidemiology</h2>

The epidemiology segment also provides the Polymyositis epidemiology data and findings across the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

<ul>
	<li>The total prevalent population of Polymyositis in the 7MM countries was estimated to be 58,913 cases in 2020.</li>
	<li>As per the estimates, the United States had the highest prevalent population of Polymyositis in 2020. Among the EU5 countries, Germany had the highest prevalent population of Polymyositis with 4,254 cases, followed by France in 2020. On the other hand, Spain had the lowest prevalent population of 3,068 cases in 2020.</li>
</ul>

<h2>Scope of the Report</h2>

<ul>
	<li>Polymyositis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis, and treatment patterns.</li>
	<li>Polymyositis Epidemiology Report and Model provide an overview of the risk factors and global trends of Polymyositis in the seven major markets (7MM: US, France, Germany, Italy, Spain, UK, and Japan).</li>
	<li>The report provides insight into the historical and forecasted patient pool of Polymyositis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan.</li>
	<li>The report helps recognize the growth opportunities in the 7MM concerning the patient population.</li>
	<li>The report assesses the disease risk and burden and highlights the unmet needs of Polymyositis.</li>
	<li>The report provides the segmentation of the Polymyositis epidemiology by prevalent cases of Polymyositis in the 7MM.</li>
	<li>The report provides the segmentation of the Polymyositis epidemiology by gender-specific cases of Polymyositis in the 7MM.</li>
	<li>The report provides the segmentation of the Polymyositis epidemiology by phenotype-specific cases of Polymyositis in the 7MM.</li>
	<li>The report provides the Polymyositis epidemiology segmentation by age-specific Polymyositis cases in the 7MM.</li>
</ul>

<h2>Report Highlights</h2>

<ul>
	<li>10-year Forecast of Polymyositis epidemiology</li>
	<li>7MM Coverage</li>
	<li>Prevalent Cases of Polymyositis</li>
	<li>Gender-specific Cases of Polymyositis</li>
	<li>Age-specific Cases of Polymyositis</li>
</ul>

<h2>KOL Views</h2>

We interview KOLs and obtain SME&rsquo;s opinions through primary research to fill the data gaps and validate our secondary research. The opinion helps understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

<h2>Key Questions Answered</h2>

<ul>
	<li>What are the major factors that will drive the change in the patient population in Polymyositis during the forecast period (2018&ndash;2030)?</li>
	<li>What are the key findings pertaining to the Polymyositis epidemiology across 7MM, and which country will have the highest number of patients during the forecast period (2018&ndash;2030)?</li>
	<li>What would be the total number of patients with Polymyositis across the 7MM during the forecast period (2018&ndash;2030)?</li>
	<li>Among the EU5 countries, which country will have the highest number of patients during the forecast period (2018&ndash;2030)?</li>
	<li>At what CAGR is the patient population expected to grow in the 7MM forecast period (2018&ndash;2030)?</li>
	<li>What are the disease risk, burdens, and unmet needs of Polymyositis?</li>
	<li>What are the currently available treatments for Polymyositis?</li>
</ul>

<h2>Reasons to buy</h2>

Polymyositis Epidemiology report will allow the user to:

<ul>
	<li>Develop business strategies by understanding the trends shaping and driving the global Polymyositis market.</li>
	<li>Quantify patient populations in the global Polymyositis market to improve product design, pricing, and launch plans.</li>
	<li>Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Polymyositis therapeutics in each market covered.</li>
	<li>Understand the magnitude of the Polymyositis population by its prevalent cases.</li>
	<li>Understand the magnitude of the Polymyositis population by its gender-specific cases.</li>
	<li>Understand the magnitude of the Polymyositis population by its age-specific cases.</li>
	<li>The Polymyositis epidemiology report and model were written and developed by Masters and PhD level epidemiologists.</li>
	<li>The Polymyositis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based on transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.</li>
</ul>

<h2>Key Assessments</h2>

<ul>
	<li>Patient Segmentation</li>
	<li>Disease Risk and Burden</li>
	<li>Risk of disease by the segmentation</li>
	<li>Factors driving growth in a specific patient population</li>
</ul>

1. Key Insights

2. Report Introduction

3. Polymyositis Market Overview at a Glance

3.1. Market Share (%) of Polymyositis by Therapies in 2018

3.2. Market Share (%) of Polymyositis by Therapies in 2030

4. Executive Summary of Polymyositis

5. Polymyositis: Disease Background and Overview

5.1. Introduction

5.2. Signs and Symptoms

5.3. Etiology

5.4. Pathophysiology

5.5. Diagnosis

6. Differential Diagnosis

6.1. Treatment

7. Epidemiology and Patient Population

7.1. Key Findings

7.2. 7MM Total Prevalence of Polymyositis

7.3. Epidemiology of Polymyositis

7.4. The United States

7.4.1. Prevalence of Polymyositis in the United States

7.4.2. Gender-specific cases of Polymyositis in the United States

7.4.3. Age-specific cases of Polymyositis in the United States

7.5. EU5

7.5.1. Total Prevalence of Polymyositis in EU5

7.5.2. Germany

7.5.2.1. Gender-specific cases of Polymyositis in Germany

7.5.2.2. Age-specific cases of Polymyositis in Germany

7.5.3. France

7.5.3.1. Gender-specific cases of Polymyositis in France

7.5.3.2. Age-specific cases of Polymyositis in France

7.5.4. Italy

7.5.4.1. Gender-specific cases of Polymyositis in Italy

7.5.4.2. Age-specific cases of Polymyositis in Italy

7.5.5. Spain

7.5.5.1. Gender-specific cases of Polymyositis in Spain

7.5.5.2. Age-specific cases of Polymyositis in Spain

7.5.6. The United Kingdom

7.5.6.1. Gender-specific cases of Polymyositis in the United Kingdom

7.5.6.2. Age-specific cases of Polymyositis in the United Kingdom

7.6. Japan

7.6.1. Prevalence of Polymyositis in Japan

8. KOL Views

9. SWOT Analysis

10. Unmet Needs

11. Appendix

11.1. Report Methodology

11.2. Bibliography

12. DelveInsight Capabilities

13. Disclaimer

14. About DelveInsight

Polymyositis - Epidemiology Forecast to 2030

DelveInsight's Polymyositis - Epidemiology Forecast 2030 report delivers an in-depth understanding of the disease, historical, and forecasted epidemiology of Polymyositis..